drugset
drugset / Trial / NCT06590857

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

NCT06590857 ↗

Phase 1/2 Active not recruiting 16 enrolled RayzeBio, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.

Timeline

Start
2024-07-19
Primary completion
2028-10
Completion
2033-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ACTINIUM DOTATATE Other / unclassified — —

Indications

Her2-receptor negative breast cancer estrogen-receptor positive breast cancer